Cidara Therapeutics Announces Positive Data From Phase 1 Clinical Trial of CD101 IV and Reports Third Quarter 2015 Financial Results
November 16, 2015 16:13 ET
|
Cidara Therapeutics, Inc.
-- Single Ascending Dose Study-Results Demonstrate Excellent Safety and Tolerability and Support Once-Weekly IV Dosing --
-- Management to Host Webcast and Conference Call Tomorrow at 8:00 a.m. ET...